Trial Outcomes & Findings for Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's Lymphoma (NCT NCT00478062)

Results Overview

Recruitment status

TERMINATED

Study phase

PHASE1/PHASE2

Target enrollment

1 participants

Primary outcome timeframe

9 months

Results posted on

2018-02-28

Participant Flow

Participant milestones

Participant milestones
Measure	Cell Vaccine After Initial Therapy for Hodgkin Lymphoma Hodgkin's antigens-GM-CSF-expressing cell vaccine after initial therapy. Hodgkin's antigens-GM-CSF-expressing cell vaccine adjuvant therapy
Overall Study STARTED	1
Overall Study COMPLETED	1
Overall Study NOT COMPLETED	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's Lymphoma

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Cell Vaccine After Initial Therapy for Hodgkin Lymphoma n=1 Participants Hodgkin's antigens-GM-CSF-expressing cell vaccine after initial therapy. Hodgkin's antigens-GM-CSF-expressing cell vaccine adjuvant therapy
Age, Categorical <=18 years	0 Participants n=5 Participants
Age, Categorical Between 18 and 65 years	1 Participants n=5 Participants
Age, Categorical >=65 years	0 Participants n=5 Participants
Sex: Female, Male Female	0 Participants n=5 Participants
Sex: Female, Male Male	1 Participants n=5 Participants

PRIMARY outcome

Timeframe: 9 months

Population: The study was closed due to slow accrual, with only one patient enrolled. No data was analyzed for any outcome measures.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: 2 years

Population: The study was closed due to slow accrual, with only one patient enrolled. No data was analyzed for any outcome measures.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: 2 years

Population: The study was closed due to slow accrual, with only one patient enrolled. No data was analyzed for any outcome measures.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: After administration of last vaccine at 9 weeks

Population: The study was closed due to slow accrual, with only one patient enrolled. No data was analyzed for any outcome measures.

Outcome measures

Outcome data not reported

Adverse Events

Cell Vaccine After Initial Therapy for Hodgkin Lymphoma

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Yvette Kasamon

Johns Hopkins Sidney Kimmel Cancer Center

Phone: 4109135018

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place